FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304895> ?p ?o ?g. }

• W4367304895 abstract "<h3>Objective:</h3> To describe baseline characteristics and treatment patterns in Huntington Disease-associated chorea by chorea severity. <h3>Background:</h3> Though multiple treatment options exist for HD-associated chorea, there are little real-world data on treatment patterns, especially across disease trajectory and variation by severity of chorea. <h3>Design/Methods:</h3> Participants were adults from “Enroll-HD”, a global observational registry for patients with HD and their families (data cut 2013 – 31 October, 2020). Data on age, sex, Total Maximal Chorea (TMC) score, vesicular monoamine transporter 2 (VMAT2) inhibitors, and antipsychotic agents (APs; typical, atypical, and other [lithium]) were collected at the baseline visit. Participants were grouped by chorea severity (TMC score categories) recorded at baseline (0–7, 8–14, 15–21, 22–28). <h3>Results:</h3> There were 10,903 participants (TMC 0–7, n=5055; TMC 8–14, n=4374; TMC 15–21, n=1310; TMC 22–28, n=164). 51% were female (51.2%, 51.5%, 51.4%, and 53.1%, respectively) and the mean age at baseline was 53.0 years (50.8, 54.5, 55.9, 54.4, respectively). Overall, VMAT2i use at baseline was 14.9% and increased with chorea severity (10.8%, 16.4%, 23.9%, 29.3%, respectively). The proportion of patients using APs at baseline was 34.5% overall and increased with chorea severity (29.9%, 35.1%, 47.8%, 57.3%, respectively). Overall, 5.8% of patients used VMAT2 inhibitors combined with APs, and combined use increased with chorea severity (3.9%, 5.8%, 11.5%, 15.9%, respectively). <h3>Conclusions:</h3> Use of medications to treat chorea was low across the spectrum of chorea severities but increased incrementally in patients with greater chorea severity. Use of a combination of VMAT2 inhibitors and APs at baseline was low but increased as chorea severity increased. These data suggest that HD-associated chorea may be under treated globally. More data are needed to understand chorea treatment considerations and the utility of VMAT2 inhibitors and APs for treating HD-associated chorea and comorbidities. <b>Disclosure:</b> Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Neuroscience. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Michael J. Fox Foundation. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva Pharmaceuticals. The institution of Dr. Furr-Stimming has received research support from Cures within Reach. The institution of Dr. Furr-Stimming has received research support from Huntington’s Disease Society of America. The institution of Dr. Furr-Stimming has received research support from Roche/Genetech. The institution of Dr. Furr-Stimming has received research support from Uniqure. The institution of Dr. Furr-Stimming has received research support from CHDI. The institution of Dr. Furr-Stimming has received research support from Huntington Study Group/Neurocrine. The institution of Dr. Furr-Stimming has received research support from NIH/University of Iowa. The institution of Dr. Furr-Stimming has received research support from Sage Therapeutics. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Reshef has received personal compensation for serving as an employee of Teva. Ms. Willock has received personal compensation for serving as an employee of HCD Economics. Rinat Ribalov has received personal compensation for serving as an employee of TEVA. Miss Brighton has nothing to disclose. Dr. Leo has received personal compensation for serving as an employee of Teva Pharmaceutical Industries." @default.
• W4367304895 created "2023-04-29" @default.
• W4367304895 creator A5015284385 @default.
• W4367304895 creator A5035661780 @default.
• W4367304895 creator A5047715924 @default.
• W4367304895 creator A5058970311 @default.
• W4367304895 creator A5067840969 @default.
• W4367304895 creator A5072229305 @default.
• W4367304895 creator A5091005645 @default.
• W4367304895 date "2023-04-25" @default.
• W4367304895 modified "2023-09-30" @default.
• W4367304895 title "Baseline Characteristics and Treatment Patterns of a Global Huntington Disease Population Stratified by Chorea Severity (P2-11.011)" @default.
• W4367304895 doi "https://doi.org/10.1212/wnl.0000000000202020" @default.
• W4367304895 hasPublicationYear "2023" @default.
• W4367304895 type Work @default.
• W4367304895 citedByCount "0" @default.
• W4367304895 crossrefType "proceedings-article" @default.
• W4367304895 hasAuthorship W4367304895A5015284385 @default.
• W4367304895 hasAuthorship W4367304895A5035661780 @default.
• W4367304895 hasAuthorship W4367304895A5047715924 @default.
• W4367304895 hasAuthorship W4367304895A5058970311 @default.
• W4367304895 hasAuthorship W4367304895A5067840969 @default.
• W4367304895 hasAuthorship W4367304895A5072229305 @default.
• W4367304895 hasAuthorship W4367304895A5091005645 @default.
• W4367304895 hasConcept C126322002 @default.
• W4367304895 hasConcept C187212893 @default.
• W4367304895 hasConcept C2778868616 @default.
• W4367304895 hasConcept C2779134260 @default.
• W4367304895 hasConcept C2908647359 @default.
• W4367304895 hasConcept C71924100 @default.
• W4367304895 hasConcept C99454951 @default.
• W4367304895 hasConceptScore W4367304895C126322002 @default.
• W4367304895 hasConceptScore W4367304895C187212893 @default.
• W4367304895 hasConceptScore W4367304895C2778868616 @default.
• W4367304895 hasConceptScore W4367304895C2779134260 @default.
• W4367304895 hasConceptScore W4367304895C2908647359 @default.
• W4367304895 hasConceptScore W4367304895C71924100 @default.
• W4367304895 hasConceptScore W4367304895C99454951 @default.
• W4367304895 hasLocation W43673048951 @default.
• W4367304895 hasOpenAccess W4367304895 @default.
• W4367304895 hasPrimaryLocation W43673048951 @default.
• W4367304895 hasRelatedWork W133380858 @default.
• W4367304895 hasRelatedWork W2071470135 @default.
• W4367304895 hasRelatedWork W2094055632 @default.
• W4367304895 hasRelatedWork W2100051582 @default.
• W4367304895 hasRelatedWork W2117105431 @default.
• W4367304895 hasRelatedWork W2160939175 @default.
• W4367304895 hasRelatedWork W2181558538 @default.
• W4367304895 hasRelatedWork W2276803347 @default.
• W4367304895 hasRelatedWork W2413260837 @default.
• W4367304895 hasRelatedWork W2413698845 @default.
• W4367304895 isParatext "false" @default.
• W4367304895 isRetracted "false" @default.
• W4367304895 workType "article" @default.